Related Experiment Video
Updated: Apr 20, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
117
Durable response to brigatinib in a ROS1 fusion-positive inflammatory myofibroblastic tumor
Gabriela Alamilla-García1, Oscar Tahuahua-Flores2, Alejandro Soriano-Maya3
1Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City, Mexico.
Cancer Chemotherapy and Pharmacology
|April 18, 2026
Summary
No abstract available in PubMed .
Keywords:
BrigatinibInflammatory myofibroblastic tumorNext-generation sequencing.ROS1 fusionSarcomaTFG–ROS1 gene fusionMore Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.4K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.9K
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:56Treatment Resistent Cancers
1.5K
1.5K